NCT02061137View on ClinicalTrials.gov

Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Rett's Syndrome
Interventions
DRUG

fingolimod (FTY720)

0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months

Trial Locations (1)

4056

Department of Neuropediatrics - University Children's Hospital, Basel

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University Hospital, Basel, Switzerland

OTHER